Chronic Lymphocytic Leukemia Pipeline Summary

DelveInsight’s, “Chronic Lymphocytic Leukemia - Pipeline Insight, 2026” report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Chronic Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Lymphocytic Leukemia: Understanding

Chronic Lymphocytic Leukemia: Overview

Chronic lymphocytic leukemia (CLL) is an indolent lymphoproliferative malignancy characterized by the clonal proliferation and accumulation of mature but immunologically dysfunctional B lymphocytes. CLL and small lymphocytic lymphoma (SLL) are considered the same disease biologically and immunophenotypically, with CLL predominantly involving circulating blood and SLL presenting mainly with lymph-node involvement. The abnormal B cells can accumulate in the peripheral blood, bone marrow, lymph nodes, and spleen.

The exact cause of CLL remains unknown, although genetic factors are considered more important than environmental factors. A familial component has been identified, with first-degree relatives of individuals with CLL having an increased risk of developing the disease. Reported environmental or occupational associations include exposure to certain chemicals, benzene and other solvents, radiation, and tobacco use; however, the source notes that some of these associations have not been conclusively established.

CLL pathogenesis involves the development and subsequent expansion of a clonal population of malignant B lymphocytes. The process may begin with monoclonal B-cell lymphocytosis (MBL), followed by additional genetic abnormalities or changes in the bone-marrow microenvironment that promote progression to CLL/SLL. Abnormal B-cell receptor signaling contributes to the survival and proliferation of these cells. The neoplastic B cells can evade apoptosis and accumulate in lymph nodes, bone marrow, spleen, and peripheral blood, resulting in lymphocytosis, lymphadenopathy, splenomegaly, and cytopenias. Dysfunction of normal B cells can also cause hypogammaglobulinemia and increased susceptibility to infections.

Diagnosis of CLL generally involves evaluation of the peripheral blood, including a complete blood count and peripheral blood smear, which may demonstrate persistent lymphocytosis and characteristic smudge cells. Flow cytometry is used to establish the clonality and immunophenotype of circulating B cells, typically showing co-expression of CD5, CD19, and CD23 with light-chain restriction. Fluorescence in situ hybridization (FISH) can identify important cytogenetic abnormalities, including del(17p), del(11q), del(13q), and trisomy 12, while assessment of TP53 and IGHV status contributes to risk stratification. Bone-marrow examination and imaging may be used as part of the broader diagnostic and disease-assessment workup.

Treatment depends on disease activity, symptoms, genetic risk, disease stage, and patient fitness. Asymptomatic or early-stage CLL is generally managed initially with observation rather than immediate treatment. Treatment is initiated when active disease develops, such as progressive lymphocytosis, symptomatic or progressive lymphadenopathy/splenomegaly, worsening anemia or thrombocytopenia from bone-marrow failure, significant constitutional symptoms, or poorly responsive autoimmune cytopenias. For patients requiring systemic therapy, treatment approaches include targeted agents such as BTK inhibitors (e.g., ibrutinib and acalabrutinib), the BCL-2 inhibitor venetoclax, monoclonal antibodies such as rituximab and obinutuzumab, and, in selected patients, chemoimmunotherapy or other agents. Treatment selection is guided particularly by abnormalities such as del(17p)/TP53 mutation and IGHV status, as well as patient fitness and comorbidities.

"Chronic Lymphocytic Leukemia- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Lymphocytic Leukemia pipeline landscape is provided which includes the disease overview and Chronic Lymphocytic Leukemia treatment guidelines. The assessment part of the report embraces, in depth Chronic Lymphocytic Leukemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Lymphocytic Leukemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lymphocytic Leukemia R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Lymphocytic Leukemia.

Chronic Lymphocytic Leukemia Emerging Drugs Chapters

This segment of the Chronic Lymphocytic Leukemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Lymphocytic Leukemia Emerging Drugs

• Nemtabrutinib: Merck & Co., Inc.

Nemtabrutinib is an investigational oral, reversible, non-covalent BTK inhibitor that suppresses oncogenic B-cell receptor signaling with activity against wild-type BTK and BTK pathway mutants. Nemtabrutinib aims to address a common mechanism of resistance with currently available irreversible, covalent BTK inhibitors by binding in an alternative way to the BTK protein. Nemtabrutinib was acquired as part of the acquisition of ArQule, Inc. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Lymphocytic Leukemia.

• Bexobrutideg: Nurix Therapeutics/ Roche

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of Bruton’s tyrosine kinase (BTK) for the treatment of relapsed or refractory B-cell malignancies and potentially diseases in immunology and neurology. BTK is a central signaling node controlling B cell growth, development and immunologic activity. Unlike conventional BTK inhibitors, which block BTK kinase activity, bexobrutideg harnesses the body's natural protein disposal system. Bexobrutideg selectively eliminates BTK protein from cells, removing both its kinase activity and scaffolding function, potentially overcoming existing treatment-emergent resistance mutations and unlocking new therapeutic potential of targeting BTK. This drug is being developed by Nurix and Roche as a potential best-in-class therapy across oncology, immunology and neurology. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Chronic Lymphocytic Leukemia.

• MS-553: MingSight Pharmaceuticals, Inc.

MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKC?, a signaling molecule immediately downstream of BTK and PLC?2 in the B-cell receptor (BCR) pathway. As PKC? is downstream of both BTK and PLC?2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKC? signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Chronic Lymphocytic Leukemia.

• Surzetoclax (ABBV-453): AbbVie

ABBV-453, a next-generation BCL-2 inhibitor, was designed for enhanced molecular and biological properties to improve upon the patient experience relative to available therapies. Specifically, incorporation of macrocyclic elements into the hot-spot binding regions of BCL-2 afforded a constrained molecule with high potency, selectivity and durable in vivo activity at low doses. As a BCL-2 inhibitor, surzetoclax is designed to inhibit the function of the BCL-2 protein. BCL-2 is involved in preventing apoptosis, or programmed cell death, and is overexpressed in CLL cells, inhibition of BCL-2 is therefore intended to restore the apoptotic process in malignant cells. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Lymphocytic Leukemia.

• LMY-920: Luminary Therapeutics

LMY-920 is an autologous BAFF-ligand–based chimeric antigen receptor T-cell (CAR-T) therapy developed by Luminary Therapeutics for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL). The therapy uses autologous CD4+ and CD8+ T cells that are genetically engineered using the TcBuster non-viral transposon system to express a CAR incorporating a BAFF-ligand domain. This BAFF-ligand CAR is designed to recognize and bind the three members of the BAFF receptor family including BAFF-R/BR3, TACI, and BCMA which are expressed on B-lineage malignancies, including CLL. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Chronic Lymphocytic Leukemia.

Further product details are provided in the report……..

Chronic Lymphocytic Leukemia: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Lymphocytic Leukemia drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Lymphocytic Leukemia

There are approx. 110+ key companies which are developing the therapies Chronic Lymphocytic Leukemia. The companies which have their Chronic Lymphocytic Leukemia drug candidates in the most advanced stage, i.e. Phase III include, Merck & Co., Inc., and others.

• Phases

DelveInsight’s report covers around 120+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Chronic Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Lymphocytic Leukemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Lymphocytic Leukemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Lymphocytic Leukemia drugs.

Chronic Lymphocytic Leukemia Report Insights

• Chronic Lymphocytic Leukemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Lymphocytic Leukemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Lymphocytic Leukemia drugs?
• How many Chronic Lymphocytic Leukemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Lymphocytic Leukemia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Lymphocytic Leukemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Lymphocytic Leukemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Merck & Co., Inc.
• Nurix Therapeutics
• Roche
• MingSight Pharmaceuticals, Inc.
• AbbVie
• Luminary Therapeutics
• Catapult Therapeutics
• Fate Therapeutics
• CytoCares
• Oqory, Inc.
• BeOne Medicines
• Genmab
• Umoja Biopharma
• AstraZeneca
• Genventis Bio Inc.

Key Products

• Nemtabrutinib
• MK-1045
• Bexobrutideg
• MS-553
• Surzetoclax (ABBV-453)
• LMY-920
• CAP-100
• FT819
• CC312
• ROR1 ADC
• CD25 ADC
• Tacabrutideg
• Epcoritamab
• UB-VV111
• AZD5492
• Surovatamig
• GVT-HM-A101